NCI Office of Cancer Centers (OCC) Learning Series

The Clinical Assay Develoment Program - A Resorce for Assay Validation

March 13, 2012 from
2:00 to 3:30 PM ET

Researchers who have discovered predictive or prognostic molecular features often do not have the resources to analytically validate their findings into a “locked down” assay. That’s why the NCI’s Cancer Diagnosis Program in Division of Cancer Treatment and Diagnosis has initiated a program to provide resources to validate promising markers/signatures.

The Clinical Assay Development Program (CADP) is composed of contracted CLIA-accredited laboratories (Clinical Assay Development Network), a research laboratory that will also be CLIA-accredited (Molecular Characterization and Clinical Assay Development Center) at NCI-Frederick, and contracted Tissue Resources. Eligible applicants may come from industry, academia and government.

The featured speaker is:
Barbara A. Conley, M.D.
Associate Director, Cancer Diagnosis Program
NCI Division of Cancer Treatment and Diagnosis
Email Dr. Conley

Additional Speakers include:
Luke Utley, Ph.D.
Senior Scientist, DMPK
Agios Pharmaceuticals
Email Dr. Utley

Click here to see slides of the Webinar

Click here to see the transcript of the presentation: